Results 201 to 210 of about 532,025 (267)

Super‐Refractory Status Epilepticus (SRSE) in a Patient With Compound Heterozygous OPA1 Variants: Case Report and Literature Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Super‐Refractory Status Epilepticus (SRSE) is a rare, life‐threatening neurological emergency with unclear etiology in many cases. Mitochondrial dysfunction, often due to disease‐causing genetic variants, is increasingly recognized as a cause, with each gene producing distinct pathophysiological mechanisms.
Pouria Mohammadi, Lara Basovic, Christopher Michael McGraw   +2 more
wiley   +1 more source

Quantitative Electroanalysis in Ionic Liquids Using Scanning Electrochemical Cell Microscopy. [PDF]

Anal Chem
Salek S, Byers JC.
europepmc   +1 more source

Epilepsy‐Associated Variants of a Single SCN1A Codon Exhibit Divergent Functional Properties

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Pathogenic variants in SCN1A, which encodes the voltage‐gated sodium channel NaV1.1, are associated with multiple epilepsy syndromes exhibiting a range of clinical severity. SCN1A variants are reported in different syndromes, including Dravet syndrome, which is associated with loss‐of‐function, whereas neonatal/infantile‐onset ...
Lanie N. Liebovitz, Christopher H. Thompson, Linda C. Laux, Alfred L. George Jr.   +3 more
wiley   +1 more source

A damage accumulation model identifies distinct aging regimes across species. [PDF]

Nat Aging
Raz N, Yang Y, Pridham G, Shenhar B, Frenkel S, Levy T, Tlusty T, Mayo A, Alon U.   +8 more
europepmc   +1 more source

A Systematic Review and Meta‐Analysis of the Recurrence of Autoimmune Encephalitis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune encephalitis (AE) is a disease with a potential for recurrence, and patients receive immunotherapy to prevent it. However, there is no consensus on the duration of immunotherapy. This study aimed to determine the recurrence rate and identify the risk factors for AE to provide guidance on the duration of immunotherapy ...
Shangkai Bai, Sen Zhang, Haipei Zhang, Yating Zhang, Junhong Guo, Xiaoyan Yang   +5 more
wiley   +1 more source

Model-Integrated Bioequivalence (MIBE) in Generic Drug Research: Can We Ease the Bioequivalence Burden? [PDF]

Pharmaceutics
Kollipara S, Boddu R, Uppuluri CT, Saini AK.   +3 more
europepmc   +1 more source

Assessment of HIPIMS-Deposited TiN Nanostructured Thin Films as Hydrogen Permeation Barriers on Carbon Steel. [PDF]

Materials (Basel)
González-Durán R, Rodríguez-Prieto A, Camacho AM.   +2 more
europepmc   +1 more source

Quantitative systems pharmacology model of B cell immune response in mouse. [PDF]

Front Immunol
Ugolkov Y, Volkova A, Helmlinger G, Peskov K, Sokolov V.   +4 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation. [PDF]

CPT Pharmacometrics Syst Pharmacol
Mitra A, Yang X, Ortiz RH, Jomphe C, Leoni M, Gosselin NH.   +5 more
europepmc   +1 more source

Gene expression profiling identifies potential biomarkers for vaso-occlusive episodes in sickle cell disease. [PDF]

JCI Insight
Bhat V, Yoo JJ, Ponna S, Potdar AA, Patel AP, Yu GK, Gibson G, Sheehan VA.   +7 more
europepmc   +1 more source